These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Endothelial action of aldosterone--therapeutic implications from basic and clinical research]. Drelicharz L; Mikita J; Chabielska E; Chłopicki S Kardiol Pol; 2005 Oct; 63(4 Suppl 2):S409-19. PubMed ID: 20527396 [TBL] [Abstract][Full Text] [Related]
7. Implications of left ventricular asynergy. Herman MV; Gorlin R Am J Cardiol; 1969 Apr; 23(4):538-47. PubMed ID: 5781881 [No Abstract] [Full Text] [Related]
8. Effects of aldosterone and spironolactone on the isolated perfused rat heart. Moreau D; Chardigny JM; Rochette L Pharmacology; 1996 Jul; 53(1):28-36. PubMed ID: 8875599 [TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Delyani JA Kidney Int; 2000 Apr; 57(4):1408-11. PubMed ID: 10760075 [TBL] [Abstract][Full Text] [Related]
12. Cardiac potassium currents and channels. Part II: Implications for clinical practice and therapy. Monsuez JJ Int J Cardiol; 1997 Oct; 62(1):1-12. PubMed ID: 9363496 [No Abstract] [Full Text] [Related]
14. [15 years of therapy with beta-receptor blockers. Tendency for differentiation]. Kersting F; Kasper W; Meinertz T Med Klin; 1979 Aug; 74(32-33):1179-88. PubMed ID: 38385 [No Abstract] [Full Text] [Related]
15. Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. Fayssoil A; Abasse S; Silverston K J Neuromuscul Dis; 2017; 4(1):17-23. PubMed ID: 28269790 [TBL] [Abstract][Full Text] [Related]
16. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Messaoudi S; Gravez B; Tarjus A; Pelloux V; Ouvrard-Pascaud A; Delcayre C; Samuel J; Launay JM; Sierra-Ramos C; Alvarez de la Rosa D; Clément K; Farman N; Jaisser F Hypertension; 2013 Feb; 61(2):361-7. PubMed ID: 23297371 [TBL] [Abstract][Full Text] [Related]
17. Aldosterone antagonists in heart failure. Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084 [TBL] [Abstract][Full Text] [Related]
18. The renal effects of mineralocorticoid receptor antagonists. Bianchi S; Batini V; Bigazzi R Int J Cardiol; 2015 Dec; 200():20-4. PubMed ID: 26049733 [TBL] [Abstract][Full Text] [Related]
19. Aldosterone antagonists in patients with heart failure. Fayssoil A JAMA; 2010 Mar; 303(9):833; author reply 834-5. PubMed ID: 20197527 [No Abstract] [Full Text] [Related]
20. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]